ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-nectin-4/CD28 Bispecific Antibody RNDO-564

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Rondo Therapeutics.

Furthest: phase 1, since Oct 14, 20251 company-led study, 1 open or runningNext primary completion: Feb 28, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rondo Therapeutics11 open or runningphase 1since Oct 14, 2025Oct 14, 2025Feb 28, 2029phase 1 · NCT07218003

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07218003 · 149 planned · United States

Ahead

  1. Feb 28, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07218003

TargetBeta

“An immunoglobulin G (IgG)-like human tumor-targeted co-stimulatory bispecific antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) and the co-stimulatory T-cell surface glycoprotein CD28, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07218003Carcinoma, Non-Small-Cell Lung · United States1By invitationFeb 28, 2029149

How it is read

Names in the registry

  • “RNDO-564”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.